New Science Ventures

New Science Ventures is a venture capital firm which focuses on investments in the life sciences - pharmaceuticals, biologics, medical devices, and diagnostics - and information technology - high-performance semiconductors, cellular infrastructure, sensor networks, enterprise software, and storage - sectors. The firm was founded in 2004 and is based in New York, New York.

New Science Ventures invest in early and late stage companies who they feel have novel scientific approaches to address unmet needs creating improvements in performances. They also invest in companies using science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. Their team have expertise in strategy and corporate planning, operations and cost management, and leadership development.

New Science Ventures has made 60 investments. Their most recent investment was on Jul 17, 2019, when DUST Identity raised $10M. Their investments include DUST Identity, PlanetIQ, Paradigm Diagnostics, ISORG, Morrow Optics, ChromaCure, Cambridge Epigenetix, Escalier Biosciences, zeotap, Caringo, BrightVolt, Vuv Analytics, and Kateeva.

Their exited investments include Vaultive, TherOx, Seahorse Bioscience, Celleration, Dezima Pharma, Akarna Therapeutics, Lightwire, BioVex, Ception Therapeutics and FlowCardia.

New Science Ventures has raised a total of $23.9M in a single venture fund, New Science Ventures Fund III, L.P.. This fund was announced on Jun 16, 2014 and raised a total of $23.9M.